SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Poliomyelitis
Pertussis

Interventions: Biological: Diphtheria, tetanus, polio and pertussis vaccination

First Posted Date: 2011-02-02

Last Posted Date: 2017-09-11

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 342

Registration Number: NCT01287949

Locations: 🇩🇪
Sanofi Pasteur MSD investigational site, Rodgau, Germany

A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China

Phase 4

Completed

Conditions: Polio
Poliomyelitis

First Posted Date: 2011-01-17

Last Posted Date: 2013-03-29

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 5007

Registration Number: NCT01278433

Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

Phase 4

Completed

Conditions: Meningococcal Disease
Meningitis

First Posted Date: 2011-01-05

Last Posted Date: 2014-11-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 538

Registration Number: NCT01270503

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: High-Dose Trivalent Inactivated Influenza Vaccine
Biological: Trivalent Inactivated Influenza Vaccine

First Posted Date: 2010-12-13

Last Posted Date: 2016-05-16

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 300

Registration Number: NCT01258595

Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old

Phase 3

Completed

Conditions: Tetanus
Pertussis
Diphtheria
Poliomyelitis

Interventions: Biological: Concomitant administration
Biological: Separate administration

First Posted Date: 2010-11-29

Last Posted Date: 2017-09-11

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 954

Registration Number: NCT01249183

Locations: 🇩🇪
Sanofi Pasteur MSD Investigational Site, Reichenbach, Germany

Study of Quadrivalent Influenza Vaccine Among Children

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Quadrivalent Influenza Vaccine, No Preservative
Biological: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative
Biological: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative

First Posted Date: 2010-11-15

Last Posted Date: 2015-07-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 4363

Registration Number: NCT01240746

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Phase 2

Completed

Conditions: Clostridium Difficile Infection
Diarrhea

Interventions: Biological: Clostridium difficile toxoids A and B (Low-dose without adjuvant)
Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant)
Biological: Clostridium difficile toxoids A and B (Low-dose with adjuvant)
Biological: Clostridium difficile toxoids A and B (high-dose without adjuvant)

First Posted Date: 2010-10-29

Last Posted Date: 2018-07-18

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 650

Registration Number: NCT01230957

Study of Quadrivalent Influenza Vaccine Among Adults

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative
Biological: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative

First Posted Date: 2010-10-11

Last Posted Date: 2013-10-23

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 739

Registration Number: NCT01218646

Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

Phase 4

Completed

Conditions: Influenza

First Posted Date: 2010-10-06

Last Posted Date: 2018-09-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 240

Registration Number: NCT01215669

Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV

Phase 3

Completed

Conditions: Varicella
Japanese Encephalitis

Interventions: Biological: Varicella Vaccine
Biological: JE-CV Vaccine

First Posted Date: 2010-08-27

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 454

Registration Number: NCT01190228

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy